Avalo Therapeutics AVTX Income Statement (2014-2026)

NASDAQ AVTX
$8.51 +1.35 (+18.78%)
As of: Nov 11, 2026 · 3:59 PM EST
Reported Financials

Avalo Therapeutics Quarterly Income Statement

Periods 49 quarters
Latest Sep 2026

Avalo Therapeutics reported revenue of $4.25M and net income of -$19.87M for the quarter ended Sep 2026. This income statement covers 49 quarters of results from Sep 2014 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
0.22M1.17M1.03M14.95M0.90M0.48M0.64M0.24M0.57M0.25M0.19M1.15M1.10M0.06M0.80M2.76M4.25M
Cost of RevenueCost of Rev
0.42M0.72M1.57M0.53M0.62M0.55M0.71M0.25M-0.22M0.08M0.34M0.71M-0.09M
Gross Profit
-0.21M0.45M-0.53M14.42M0.28M-0.08M-0.07M-0.01M0.79M-0.08M-0.34M-0.47M0.28M0.06M
Operating items
Amortization - Intangibles
0.27M0.04M
Research & DevelopmentR&D
11.51M9.58M8.51M7.04M6.17M6.01M4.66M1.25M1.87M2.12M4.60M9.54M8.18M9.12M14.07M13.62M13.27M14.05M23.42M15.05M
Selling, General & AdministrativeSG&A
5.98M11.68M2.78M3.28M2.96M2.71M2.43M2.49M2.68M3.19M4.53M4.29M5.23M5.55M5.24M5.58M6.53M6.85M8.10M8.35M
Other Operating ExpensesOther Opex
0.69M0.76M1.57M0.53M0.62M0.55M0.71M0.25M3.69M27.46M0.45M-0.71M0.09M6.57M
Operating ExpensesOpex
18.18M22.03M12.86M10.85M9.75M9.27M7.79M3.99M8.23M32.77M9.58M13.11M13.50M14.67M19.32M19.20M19.80M20.90M31.52M23.40M
Operating IncomeOp. Inc
-17.96M-20.85M-11.83M4.10M-8.86M-8.79M-7.15M-3.75M-7.66M-32.77M-9.58M-12.86M-13.31M-14.67M-19.32M-19.20M-19.74M-20.90M-31.52M-23.40M
Non-operating items
Non Operating Interest Expenses
Goodwill impairment chargesGoodwill Impair.
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-0.03M0.08M0.03M-0.07M-0.58M-0.93M
Other Non Operating IncomeOther Non Op Inc.
-0.02M-0.03M-0.02M79.28M-112.05M-36.03M26.47M0.38M-0.01M0.00M0.01M0.48M-1.01M0.21M
Non Operating IncomeNon Op. Inc.
-1.18M-1.19M-1.15M-0.90M-0.95M-1.16M-1.04M-1.47M-0.52M-88.52M108.05M35.88M-21.91M1.53M-1.43M-11.42M6.15M1.28M-4.82M4.46M
Net income details
EBIT
-17.96M-20.85M-11.83M4.10M-8.86M-8.79M-7.15M-3.75M-7.66M-32.77M-9.58M-12.86M-13.31M-14.67M-19.32M-19.20M-19.74M-20.90M-31.52M-23.40M
EBT
-19.15M-22.04M-12.98M3.20M-9.80M-9.95M-8.19M-5.22M-8.18M-121.28M98.47M23.02M-35.23M-13.14M-20.75M-30.61M-13.59M-19.62M-36.34M-18.94M
Tax ProvisionsTaxes
0.00M0.01M0.01M0.01M0.01M0.01M0.01M0.01M-0.01M0.01M0.01M-0.01M0.11M0.01M0.02M0.01M0.13M0.01M0.02M0.01M
Income After Tax
-19.15M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.63M-13.72M-19.63M-36.36M-18.95M
Income from Continuing OperationsIncome (Continuing)
-19.13M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.63M-13.72M-19.63M-36.36M-18.95M
Income from Discontinued OperationsIncome (Discontinued)
-0.07M
Consolidated Net IncomeConsol Net Inc.
-19.20M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.80M-30.55M-13.69M-19.70M-36.94M-19.87M
Income towards Parent CompanyParent Net Inc
-19.20M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.63M-13.76M-19.63M-36.36M-18.95M
Net Income towards Common StockholdersNet Income
-19.20M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.63M-13.76M-19.63M-36.36M-18.95M
Additional items
EPS (Basic)
-2.21-2.35-1.380.34-1.04-0.85-0.59-0.11-0.17-141.1495.214.15-7.98-1.25-1.92-2.19-1.03-0.98-0.83-0.34
EPS (Diluted)
-2.30-2.35-1.380.34-1.04-0.85-0.59-0.11-29.41-141.1412.872.14-4.71-1.25-1.92-2.19-1.03-0.98-0.83-0.34
Shares Outstanding
8.69M9.40M9.40M9.41M9.41M11.72M13.97M46.76M46.76M0.86M1.03M5.55M4.43M10.51M10.83M14.00M13.40M20.11M43.60M55.06M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
8.35M9.40M9.40M9.41M9.41M11.72M13.97M46.76M0.28M0.86M7.65M10.78M7.50M10.51M10.83M14.00M13.40M20.11M43.60M55.06M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
9.40M9.40M9.41M9.41M9.43M13.20M14.04M46.76M0.86M1.03M5.55M4.43M10.83M10.84M14.00M13.40M20.11M43.60M53.92M
EBITDA
-17.32M-20.44M-11.46M4.48M-8.47M-8.41M-6.76M-2.58M-7.62M-32.73M-9.54M-12.83M-13.24M-14.53M-19.18M-19.14M-19.73M-20.88M-31.50M-23.38M
Interest ExpensesInt Expense
Tax Rate
0.16%0.01%

Avalo Therapeutics Income Statement API

Pull Avalo Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=AVTX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY